Immunitybio Inc（IBRX）の株式分析IBRXImmunitybio Inc

ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. The Cancer BioShield platform is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via its IL-15 receptor agonist, ANKTIVA. The Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

ImmunityBio Inc (IBRX) is a good buy right now due to its recent strong performance and positive market sentiment. The current price is $10.51, which is near the Fibonacci resistance level of $10.551, indicating potential for further gains. The stock has shown a remarkable year-to-date change of +420.30%, reflecting strong investor interest. Additionally, the RSI is at 73.072, suggesting that the stock is in a strong momentum phase, although it is approaching overbought territory. The main risk is the negative net income, which was -632,782,000 USD in Q1 2026, indicating ongoing financial challenges that investors should monitor closely.